Vimarsana
Biggest News Aggregation in the World

Page 8 - Human Use News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Human Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Human Use Today - Breaking & Trending Today

Sanofi: Dupixent recommended for EU approval by the CHMP to treat patients with COPD - Vimarsana News

Sanofi: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3

Update On FDA Priority Review Of Dupixent® (Dupilumab) For The Treatment Of COPD Patients With Type 2 Inflammation - Vimarsana News

Update On FDA Priority Review Of Dupixent® (Dupilumab) For The Treatment Of COPD Patients With Type 2 Inflammation

TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food a

Source: menafn.com
AbbVie: Risankizumab Recommended For EU Approval For Moderately-Severely Active Ulcerative Colitis - Vimarsana News

AbbVie: Risankizumab Recommended For EU Approval For Moderately-Severely Active Ulcerative Colitis

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - AbbVie Inc. (ABBV) announced Friday that Friday that Risankizumab (SKYRIZI) has been recommended for European Union approval for the treatment of adults with

SIFI S.p.A.: SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis - Vimarsana News

SIFI S.p.A.: SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis

ACI SANT'ANTONIO, Italy, May 31, 2024 /PRNewswire/ -- SIFI announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive

Regeneron : FDA Extends Review Period For Dupixent As COPD Treatment By Three Month - Vimarsana News

Regeneron : FDA Extends Review Period For Dupixent As COPD Treatment By Three Month

(RTTNews) - The U.S. Food and Drug Administration has extended by three months the target action date of its priority review of the supplemental B...